Boniva print ad hyped efficacy, says DDMAC

Share this article:
Boniva print ad hyped efficacy, says DDMAC
Boniva print ad hyped efficacy, says DDMAC
A print ad for Genentech's Boniva overstated the osteoporosis drug's efficacy, said the FDA's Division of Drug Marketing, Advertising and Communication in an untitled letter.

The agency took issue with the claim in the ad, which features Sally Field, that: “Studies show, after a year on Boniva, 9 out of 10 women stopped and reversed their bone loss.”

The claim, said DDMAC, “is not supported by substantial evidence or substantial clinical experience” but rather “a per-protocol post-hoc responder analysis that the clinical study was not adequately designed to evaluate.”

Genentech, said FDA, is pulling violative promotional materials for the drug featuring that claim.

The ad that prompted the letter ran in Parade Magazine. It features an image of Field sitting on a pier, with the headline: “I wanted to stop my bone loss. But I did more. I reversed it with Boniva.”

Field has served as the face of the brand since 2006, when Roche and GlaxoSmithKline launched their “Rally with Sally for Bone Health” campaign.”
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.